Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

President Donald Trump's administration warned on Tuesday the United States could impose fees or restrictions on European service providers in response to what it called “discriminatory” actions ...